Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Predicted Market Size Of The Leber Congenital Amaurosis Industry By 2029?

Over the last few years, the leber congenital amaurosis market has experienced stable growth. The market is projected to increase from $1.01 billion in 2024 to $1.06 billion in 2025, with a compound annual growth rate (CAGR) of 4.9%. Factors contributing to this historic period growth include increased awareness of uncommon eye conditions, additional government funding, enhanced diagnostic methods, the expansion of research institutions specializing in ophthalmology, and initiatives advocating for patients.

In the coming years, the market size for leber congenital amaurosis is projected to experience robust growth, escalating to $1.31 billion by 2029 with a compound annual growth rate (CAGR) of 5.5%. Increased investment in gene therapy, a high occurrence rate of inherited retinal illnesses, approval of new treatments, a surge in clinical trials, and a rise in healthcare spending can be credited for this anticipated growth during the forecast period. Prominent trends projected for the forecast period include the advent of CRISPR-based treatments, heightened synergy among biotech firms, progression of personalised medicine, the growth of teleophthalmology, and technological advancements in retinal imaging.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22033&type=smp

Which Growth Drivers Are Shaping The Leber Congenital Amaurosis Market Outlook?

The growth of the leber congenital amaurosis (LCA) market is anticipated to be driven by the rising prevalence of inherited retinal diseases. These conditions are genetic disorders that affect the retina – the area of the eye sensitive to light and critical for vision. The surge in inherited retinal diseases can be linked to improvements in genetic testing, increased awareness and diagnosis, as well as expanded life expectancy. Enhanced genetic examination procedures have simplified the process of detecting inherited retinal diseases, thus, enabling the recognition of more cases. Leber congenital amaurosis plays a significant role in expanding our understanding of inherited retinal diseases by uncovering genetic alterations and disease mechanisms, paving the way for the creation of personalized therapies and treatments. It was reported in January 2025 by the House of Commons Library of the UK Parliament, a governmental administration based in the UK, that the number of people affected by inherited retinal diseases in the UK in 2024 was approximately 25,000, marking a yearly upsurge of 2%. Thus, the continuous growth in the occurrence of inherited retinal diseases is pushing the leber congenital amaurosis market forward.

How Is The Global Leber Congenital Amaurosis Market Broken Down By Segment?

The leber congenital amaurosismarket covered in this report is segmented –

1) By Treatment Type: Gene Therapy; Pharmaceutical Drugs; Retinal Prosthesis; Assistive Devices; Other Treatments

2) By Age Of Onset: Congenital Leber Congenital Amaurosis (LCA) (From Birth); Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years); Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)

3) By Distribution Channel:; Direct Tender; Retail Sales

4) By End User: Hospitals; Specialized Eye Clinics; Ophthalmology Research Centers; Home Care Settings; Other End Users

Subsegments:

1) By Gene Therapy: RPE65 Gene Replacement Therapy; CRISPR-Based Gene Editing; AAV (Adeno-Associated Virus) Vector Therapy; Emerging Experimental Gene Therapies

2) By Pharmaceutical Drugs: Retinoid-Based Therapies; Neuroprotective Agents; Anti-Inflammatory Drugs; Antioxidant Therapies

3) By Retinal Prosthesis: Implantable Retinal Chips; Artificial Retinal Stimulation Devices; Bionic Eye Technology

4) By Assistive Devices: Low Vision Aids; Screen Readers and Braille Devices; Mobility Aids for Vision Impairment

5) By Other Treatments: Stem Cell Therapy; Optogenetics-Based Treatments; Visual Rehabilitation Programs; Nutritional and Dietary Interventions

Which Market Trends Are Expected To Define The Future Of The Leber Congenital Amaurosis Market?

In the Leber congenital amaurosis market, major companies are focusing on developing innovative solutions, such as RNA-based treatments to improve vision restoration and disease management. RNA-based treatments use RNA molecules to treat diseases by targeting genetic processes. These include mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. For instance, in January 2025, Laboratoires Théa S.A.S., a France-based pharmaceutical company, launched Sepul Bio, a dedicated business unit aimed at advancing RNA therapies for inherited retinal diseases, explicitly targeting sepofarsen for Leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. With the successful dosing of the first patient in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is poised to make significant strides in addressing these rare genetic disorders.

Who Are The Primary Market Leaders In The Leber Congenital Amaurosis Market?

Major companies operating in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OÜ, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., IVERIC bio Inc. (formerly Ophthotech Corporation), Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/leber-congenital-amaurosis-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Leber Congenital Amaurosis Market?

North America was the largest region in the leber congenital amaurosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leber congenital amaurosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22033&type=smp

Browse Through More Reports Similar to the Global Leber Congenital Amaurosis Market 2025, By The Business Research Company

Congenital Diaphragmatic Hernia Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

Vitreoretinal Surgery Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vitreoretinal-surgery-devices-global-market-report

Retinal Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model